Drug intelligence / Profile preview

elezanumab

Development stage: Phase 2
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Elezanumab is a fully human monoclonal antibody developed by AbbVie that targets repulsive guidance molecule A (RGMa), a protein known to inhibit axonal outgrowth and neuronal regeneration in the central nervous system. By binding to RGMa, elezanumab is designed to promote neuroregeneration and functional recovery following CNS injury. It is being investigated as a potential treatment for spinal cord injuries, multiple sclerosis (both relapsing and progressive forms), and acute ischemic stroke. Elezanumab has received Orphan Drug designation for spinal cord injury from the FDA[2][3][5].

Other names: elezanumabABT-555ABT555ABT 555AE12-1Y-QLAE-12-1Y-QLAE 12-1Y-QL

Targets

RGMA (Repulsive guidance molecule A)

Beyond the preview

Go deeper on elezanumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elezanumab.

Explore the full profile